Discovery Laboratories Announces Newly-Published Study Compares SURFAXIN LS and CUROSURF in Well-Established Model of Respiratory Distress Syndrome

Discovery Laboratories, Inc. (NASDAQ: DSCO) reported that data from a preclinical study of SURFAXIN LS™ (lyophilized KL4 surfactant) was recently published in the May issue of Pediatric Research. The results of the study demonstrate that improvements in lung function following administration of SURFAXIN LS compares favorably to improvements in lung function following administration with Curosurf®. In addition, physiologic findings suggest that SURFAXIN LS may have a more favorable safety profile at the time of surfactant administration. The study was conducted in the preterm lamb model of surfactant deficiency, a preclinical model recognized by the neonatal academic community as a well-established surrogate for human respiratory distress syndrome (RDS). Curosurf is the current global, market-leading, animal-derived surfactant. SURFAXIN LS, is being developed as a lyophilized dosage form of SURFAXIN®, the first synthetic, peptide-containing surfactant approved by the U.S. Food and Drug Administration (FDA) for use in neonatal medicine.